7:14 am Quest Diagnostics beats by $0.02, beats on revs; guides FY14 EPS in-line, revs in-line (DGX) : Reports Q2 (Jun) earnings of $1.08 per share, excluding non-recurring items, $0.02better than the Capital IQ Consensus Estimate of $1.06; revenues rose 4.8% year/year to $1.90 bln vs the $1.88 bln consensus. Co issues in-line guidance for FY14, sees EPS of $4.00-4.10, excluding non-recurring items, vs. $4.03 Capital IQ Consensus Estimate; sees FY14 rev growth of +2.5%-3.5% vs prior guidance of +2%-4%. The new guidance computes to FY14 revenue of $7.32-7.40 bln vs. $7.35 bln Capital IQ Consensus Estimate.
Quest Diagnostics Earnings Report
Quest Diagnostics beats by $0.02, beats on revs; guides FY14 EPS in-line, revs in-line (DGX) : Reports Q2 (Jun) earnings of $1.08 per share, excluding non-recurring items, $0.02 better than the Capital IQ Consensus Estimate of $1.06; revenues rose 4.8% year/year to $1.90 bln vs $1.88 bln consensus.
Disclaimer:
None.
Disclaimer: This and other personal blog posts are not reviewed, monitored or endorsed by TalkMarkets. The content is solely the view of the author and TalkMarkets is not responsible for the content of this post in any way. Our curated content which is handpicked by our editorial team may be viewed here.
Comments
Log in or sign up to join the conversation.